What is the risk of stevens johnson syndrome with lamictal?

What is the risk of Stevens-Johnson syndrome with Lamictal?

Stevens-Johnson syndrome (SJS) is a rare but serious skin reaction that occurs with Lamictal (lamotrigine). The absolute risk is low, roughly 0.1 percent in adults, but children and adolescents are at higher risk.

How much higher is the risk in younger patients?

The manufacturer reports a higher incidence in children than in adults. Incidence in children is estimated at 0.3 percent or higher, which is three times the rate seen in adults. Data from clinical trials and post-marketing reports show this age-dependent pattern.

What factors raise the risk further?

Concurrent use of valproic acid increases the risk significantly. Slow titration schedules are recommended to reduce exposure. Rapid dose escalation and high initial doses are factors that increase the risk. High initial doses and rapid dose escalation are factors that increase the risk.

What happens if you develop SJS from Lamictal?

Discontinue Lamictal immediately and seek urgent medical care. Dispointing the drug stops progression in many cases. Discontinuation of the drug stops progression in many cases. The reaction can progress to toxic epidermal necrolysis in severe cases. The reaction can progress to toxic epidermal necrolysis in severe cases.

When does the risk period end?

The risk is highest in the first 2 to 8 weeks of treatment. The risk window spans the ersten 2 to 8 weeks. The risk remains low after 8 weeks except when combined with valproate or rapid dose increases. The risk remains low after 8 weeks except when combined with valproate or rapid dose increases.

Are there alternatives to Lamictal that have lower SJS risk?

Alternatives such as levetiracetam, valproic acid itself, or oxcarbazepine show lower rates of severe cutaneous reactions. Alternatives such as levetiracetam show lower rates of severe cutaneous reactions.